company background image
ONCR

Oncorus NasdaqGM:ONCR Stock Report

Last Price

US$0.43

Market Cap

US$11.1m

7D

-0.7%

1Y

-85.8%

Updated

02 Feb, 2023

Data

Company Financials +

ONCR Stock Overview

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients.

ONCR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

New

Notes are coming soon

Oncorus, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Oncorus
Historical stock prices
Current Share PriceUS$0.43
52 Week HighUS$3.26
52 Week LowUS$0.23
Beta2.43
1 Month Change53.54%
3 Month Change-25.54%
1 Year Change-85.81%
3 Year Changen/a
5 Year Changen/a
Change since IPO-97.33%

Recent News & Updates

Oncorus GAAP EPS of -$0.74 misses by $0.02

Aug 04

Recent updates

Oncorus GAAP EPS of -$0.74 misses by $0.02

Aug 04

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oct 14
We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

Jul 09

Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

May 05
Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

Feb 26
What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

Oncorus: Buy On A Dip, Potential Already Priced In At Current Levels

Feb 02

Oncorus to build viral immunotherapy clinical manufacturing facility in U.S.

Jan 04

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Jan 04
We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

Oncorus reports Q3 results

Nov 11

Shareholder Returns

ONCRUS BiotechsUS Market
7D-0.7%-0.3%1.7%
1Y-85.8%5.3%-9.1%

Return vs Industry: ONCR underperformed the US Biotechs industry which returned 3.9% over the past year.

Return vs Market: ONCR underperformed the US Market which returned -12.5% over the past year.

Price Volatility

Is ONCR's price volatile compared to industry and market?
ONCR volatility
ONCR Average Weekly Movement18.8%
Biotechs Industry Average Movement12.2%
Market Average Movement6.8%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: ONCR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: ONCR's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201582Ted Ashburnhttps://www.oncorus.com

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company’s lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus.

Oncorus, Inc. Fundamentals Summary

How do Oncorus's earnings and revenue compare to its market cap?
ONCR fundamental statistics
Market CapUS$11.09m
Earnings (TTM)-US$76.33m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ONCR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$76.33m
Earnings-US$76.33m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.94
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio24.1%

How did ONCR perform over the long term?

See historical performance and comparison